skip to: page content | links on this page | site navigation | footer (site information)

Karin A. Kook, Ph.D.

Publications

  1. Teo, S. K., Resztak, K.E., Scheffler, M.A., et al. 2002. Thalidomide in the treatment of leprosy. Microbes Infection 4:1193-1202.
  2. Noormohamed, F.H., Yoder, L., Kook, K.A., et al. Pharmacokinetics and enzymatic hydroxylation of thalidomide in patients with lepromatous leprosy (Hansen's Disease). (Submitted to Antimicrob. Agents Chemother.)
  3. Kook, K., Gabelnick, H., and Duncan, G. 2002. Pharmacokinetics of levonorgestrel 0.75 mg tablets. Contraception 66:73-76.
  4. Teo, S.K., Scheffler, M.R., Kook, K.A., et al. 2001. Thalidomide dose proportionality assessment following single doses to healthy subjects. J. Clin. Pharmacol. 41:662-667.
  5. Teo, S.K., Scheffler, M.R., Kook, K.A., et al. 2000. Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. Biopharm. Drug Disp. 21:33-40.
  6. Kaplan, G., Thomas, S., Fierer, D.S. et al. 2000. Thalidomide for the Treatment of AIDS-Associated Wasting. AIDS Res. Human Retroviruses. 16:1345-1355.
  7. Teo, S.K., Sabourin, P.J., O'Brien, K., et al. 1999. Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J. Biochem. Mol. Toxicol. 14:140-147.
  8. Noormohamed, F.H., Youle, M.S., Higgs, C.J., et al. 1999. Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immuno-deficiency virus-infected patients. AIDS Res. Human Retroviruses. 15:1047-1052.
  9. Mordes, D., Pleune, B., Poli, R., and Richard, P. "Preparation and Structure of the 17-Electron (C5R5)Mo(OH2)(dppe) (R=Me, Et) Organometallic Compounds Containing Two Gem-Terminal Hydroxide Ligards." J. Organomet. Chem. 596:64-9 (2000).
  10. Montpied, P., Weizman, A., Weizman, R., et al. 1993. Repeated swim-stress reduces the GABA A/ µ receptor subunit mRNAs in the mouse hippocampus. Mol. Brain Res. 18:267-272.
  11. Weizman, A., Weizman, R., Kook, K.A., et al. 1990. Adrenalectomy prevents the stress-induced decrease in in vivo [ 3H]Ro15-1788 binding to GABA A/benzodiazepine receptors in the mouse. Brain Res. 519:347-350.
  12. Weizman, R., Weizman, A., Kook, K.A., et al. 1989. Repeated swim stress alters brain benzodiazepine receptors measured in vivo. J. Pharmacol. Exp. Ther. 249:701-707.
  13. Deutsch, S.I., Weizman, R., Kook, K.A., et al. 1988. The role of the GABA A/benzodiazepine receptor complex in stress - in vivo approaches and potential relevance to childhood psychopathology. In Deutsch S.I. (ed.) Application of Basic Neuroscience to Child Psychiatry, Plenum Publishing Corporation.
  14. Muir, K.T., Kook, K.A., Gardner, K., et al. 1986. Reverse-phase HPLC assay for amiodarone in serum and in tears. J. Chromatogr. 374:394-399.
  15. Kook, K.A., Stimmel, G.L., Wilkins, J.N., et al. 1984. Safety and accuracy of a priori lithium loading. J. Clin. Psychiatry 46:49-51.
  16. Escobar, J.I., Mendoza, R., Kook, K.A., et al. 1984. The dexamethasone suppression test in a large outpatient clinic: Its diagnostic and predictive significance. Psychopharmacol. Bull. 20:89-92.
  17. Ray, D.S. and Kook, K.A. 1978a. Development of M13 as a single-stranded closing vector. In Single-Stranded DNA Phages. Cold Spring Harbor Meeting.
  18. Ray, D.S. and Kook, K.A. 1978b. Insertion of the Tn3 transposon into the genome of the single-stranded DNA phage M13. Gene 4:109-119.

Teaching

  1. Strategies for Non-compliant GXPs, RAPS 2000 Workshop, Washington, D.C., October 2000.
  2. Protocol Design, RAPS Drug Approval Workshop, Washington, D.C., May 1993.
  3. The FDA Review Process, Clinical Research and Development for Medical Monitoring. Pharmaceutical Manufacturers Association Education and Research Institute, Washington, D.C., May 1993 and October 1993.
  4. Nonclinical Pharmacology in Drug Development, Regulatory Affairs Professionals Society (RAPS) Drug Development Workshop, Washington, D.C., May 1992.
  5. Pharmacokinetic Principles (Seminar series), Division of Neuropharmacological Drug Products, FDA, February 1987 - March 1987.

Presentations

  1. Stevens, R.E., Gablenick, H., Duncan, G., et al. A relative bioavailability study of a new formulation of levonorgestrel 0.75 mg tablets in healthy female adults. (Poster presented at American Association of Pharmaceutical Scientists, 1999).
  2. A double-blind, controlled, dose comparison study of thalidomide in the acute treatment of erythema nodosum leprosum (ENL). Paper presented at the 15 th International Leprosy Congress, Beijing, China, 1998.
  3. Open label use of thalidomide in adults with HIV-associated wasting (Protocol W002). (Poster presented at the World AIDS Conference, Geneva, Switzerland, 1998).
  4. Nonclinical development of biological products. Paper presented at Regulatory Affairs Professionals Society Annual Meeting, 1994a.
  5. Drug development in obsessive-compulsive disorder: A model for cocaine abuse? Paper presented at the National Institute of Drug Abuse Seminar Series. 1994b.
  6. Looking at your drug through the FDA's eyes: A different perspective on "Breakthrough" science, clinical trials: New paradigms for success. Paper presented at BioTechnology, Washington, D.C. 1994c.
  7. Characterization of the benzodiazepine receptor using in vivo binding of Ro15-1788 in mice. Paper presented at The II Baltic Meeting on Pharmacology and Clinical Pharmacology at Tallinn, Estonia. 1990a.
  8. Clinical trial methodology in psychopharmacology. Paper presented at the Department of Clinical Pharmacology, Karolinska Institutet, at Stockholm, Sweden. 1990b.
  9. The efficacy of clomipramine in the treatment of OCD: Presentation of FDA position. Presented at Psychopharmacologic Drugs Advisory Committee Hearing. 1989a.
  10. The efficacy of clozapine in treatment-refractory schizophrenia: Presentation of FDA position. Presented at Psychopharmacologic Drugs Advisory Committee Hearing. 1989b.
  11. Stress-induced alteration of in vivo benzodiazepine receptor binding and function. Poster presented at the National Institutes of Health Research Day. 1988.
  12. The effects of swim stress on the occupancy of brain benzodiazepine receptors measured with [ 3H]Ro15-1788 in mice (poster). Presented at Society for Neuroscience Meeting at New Orleans, LA. 1987a.
  13. Psychiatric drug development. Presented at Department of Psychiatry Grand Rounds, University of Southern California. 1987b.
  14. Is there anything new in antidepressant therapy? Presented at American Society Hospital Pharmacists Mid-year Meeting at Las Vegas, NV. 1986.
  15. Future directions in affective disorder management. Presented at Faculty Seminar Series, University of Southern California. 1983.
  16. Development of a reverse-phase HPLC assay for amiodarone in serum and in tears. Presented at Pharmaceutics Seminar Series, University of Southern California. 1982.

 

 

Technical and Strategic Consulting to the Pharmaceutical Industry. | ©2008 Salamandra, LLC